GabrielNMannisMD

Hematology • Stanford, CA

Assistant Professor of Medicine, Stanford Cancer Institute

Join to view full profile

Dr. Mannis is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Mannis' full profile

Already have an account?

Office
300 Pasteur Dr
Stanford, CA 94305
Phone+1 650-723-4000

Education & Training

University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2011 - 2014
University of California (San Francisco)Residency, Internal Medicine, 2008 - 2011
University of California, Davis, School of MedicineClass of 2008

Certifications & Licensure

CA State Medical License 2010 - 2026
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies Start of enrollment: 2017 Sep 08
Terminated
Phase 1
Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia Start of enrollment: 2018 Oct 15
Active, not recruiting
Phase 3
Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML) Start of enrollment: 2021 Feb 09
Active, not recruiting
Phase 1, Phase 2
A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2019 Dec 02
Completed
Phase 1
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia Start of enrollment: 2022 Jun 01
Recruiting
Not Applicable
Roles: Contact
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Tuspetinib (HM43239) in Patients With Relapsed or Refractory Acute Myeloid Leukemia Start of enrollment: 2019 Mar 11
Recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
Venetoclax + Azacitidine vs. Induction Chemotherapy in AML Start of enrollment: 2021 May 20
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

The improved prognosis of-internal tandem duplication but not tyrosine kinase domain mutations in acute myeloid leukemia in the era of targeted therapy: a real-world s...
Matthew Schwede, Gladys Rodriguez, Vanessa E Kennedy, Solomon Henry, Douglas Wood
Haematologica. 2025-02-06
11 citations
Menin Inhibition With Revumenib for-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).
Ghayas C Issa, Ibrahim Aldoss, Michael J Thirman, John DiPersio, Martha Arellano
Journal of Clinical Oncology. 2025-01-01
Characterization and Clinical Outcome of Philadelphia Chromosome-Positive AML in Thrombocytopenia-Absent Radius Syndrome.
Alejandro Villar-Prados, Arman Odabas, Joshua R Menke, Kerry Kingham, Gabriel N Mannis
JCO Precision Oncology. 2024-10-01

Lectures

Adult Clinical Malignant Hematology
61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019

Press Mentions

OncLive® Presents State of the Science Summit™: Hematologic MalignanciesDecember 5th, 2017
Risk-Reducing Salpingo-Oophorectomy and Ovarian Cancer Screening in 1077 Women After BRCA TestingJanuary 28th, 2013
Study Examines Risk Reduction and Screening for Ovarian Cancer Among Women Following BRCA TestingJanuary 29th, 2016